Himalayas-1: Rinzimetostat, an Allosteric PRC2 Inhibitor Combined with Darolutamide: A Global Phase 3 Study in #mCRPC Patients Previously Treated With Abiraterone Acetate. Presente

UroToday.com· @urotoday · X·2026-10-24 00:00· 2 天前评分45

正文 · 原文

Himalayas-1: Rinzimetostat, an Allosteric PRC2 Inhibitor Combined with Darolutamide: A Global Phase 3 Study in #mCRPC Patients Previously Treated With Abiraterone Acetate. Presented by @quimmateo @VHIO, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4yGncGX #ProstateCancer #ClinicalTrials @myESMO

349 浏览 · 7 赞 · 2 转发 · 0 回复

会议摘要

2218RONCT04746300按 Rapid oral: Genitourinary tumours, prostate, penile and testis 对上

Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)

https://esmocongress.esmo.org

2220RONCT04746300按 Rapid oral: Genitourinary tumours, prostate, penile and testis 对上

Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)

https://esmocongress.esmo.org

来源：UroToday.com · x.com